A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma

NCT00542893 Phase 1 COMPLETED

This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense

Details

Lead sponsor	Genta Incorporated
Phase	Phase 1
Status	COMPLETED
Start date	2006-04
Completion	2007-09

Conditions

• Advanced Melanoma

Interventions

• Genasense® (G3139, oblimersen sodium)
• Genasense followed by DTIC; then DTIC alone
• DTIC alone; then Genasense followed by DTIC